Docetaxel for Patients With Paclitaxel-Resistant Müllerian Carcinoma

Abstract

Docetaxel is an active chemotherapeutic agent in patients with müllerian carcinoma previously treated with paclitaxel-based chemotherapy, especially in the patients who had a long taxane-free interval after a previous short response to paclitaxel.